TIDMFFWD
FastForward Innovations Limited
26 January 2021
FastForward Innovations Ltd / AIM: FFWD / Sector: Closed End
Investments
26 January 2021
FastForward Innovations Ltd ("FastForward" or, "FFWD")
Investee Company Update: EMMAC Life Sciences
FastForward Innovations Ltd, the AIM quoted company focusing on
making investments in fast growing and industry leading businesses,
notes the following announcement released today concerning investee
company EMMAC Life Sciences ('EMMAC'). FastForward has a 2.3%
interest in the issued stock of EMMAC.
The announcement is set out below without material changes or
adjustments.
EMMAC Life Sciences Group and Boiron selected for French Medical
Cannabis trial
Only European Company selected by the French Agency for the
Safety of Medicines and Health Products (ANSM)
26 January 2021, London. EMMAC Life Sciences Group ("EMMAC" or
the "Group" or the "Company"), Europe's largest independent
cannabis company, is pleased to announce that in partnership with
Paris Euronext listed Boiron (BOI.PA), it has been selected by the
French Agency for the Safety of Medicines and Health Products
("ANSM") as one of the suppliers for the forthcoming French Medical
Cannabis trial.
The trial, the first of its kind in France, will allow 3,000
patients access to medical cannabis as a treatment option for
certain indications; including chronic pain, epilepsy, oncology and
spasticity; under tightly controlled conditions. ANSM has selected
EMMAC's 20/1 and 10/10 oral solutions as second-source treatments
to be available to patients and healthcare professionals as part of
the two year trial.
The partnership combines Boiron's unparalled expertise in
plant-based medicine, with EMMAC's uniquely controlled European
supply chain, from seed to patient, in order to deliver
pharmaceutical-grade cannabis medicines that meet the strict
requirements of product quality, safety and traceability.
Valérie Lorentz-Poinsot, Chief Executive Officer of Boiron,
said: "Participating in this trial is part of our project to
provide patients in therapeutic impasse with effective solutions.
Medical cannabis is an important alternative treatment option for
the future, particularly for the management of chronic and complex
pain. We are very pleased to partner with EMMAC Life Sciences Group
in this project, and remain at the disposal of the ANSM."
Antonio Costanzo, Chief Executive Officer of EMMAC, said: "We
are proud to have been selected to be part of this important trial.
Alongside Boiron, we are pleased to share our international
experience to advance the industry's understanding of the benefits
of medical cannabis. The selection of our products by ANSM is
testament to EMMAC's scientific knowledge and rigor, as well as our
ability to provide products to the highest standards of compliance,
safety and quality."
- Ends -
About EMMAC Life Sciences Group
EMMAC Life Sciences Group is Europe's largest independent
cannabis company, bringing together pioneering science and research
with cutting-edge cultivation, extraction and production. With a
unique supply and distribution network throughout Europe, EMMAC's
vision is to bring the life-enhancing potential of cannabis to the
people who need it. For more information about EMMAC, please visit
https://www.emmac.com/ .
Contact:
For scientific enquiries please contact research@emmac.com
For general enquiries please contact info@emmac.com or visit
www.emmac.co m
CAUTIONARY STATEMENT
All statements, other than statements of historical fact, in
this news release are forward-looking statements that involve
various risks and uncertainties, including, without limitation,
statements regarding potential values, the future plans and
objectives of EMMAC Life Sciences Group. There can be no assurance
that such statements will prove to be accurate, achievable or
recognisable in the near term.
Actual results and future events could differ materially from
those anticipated in such statements. These and all subsequent
written and oral forward-looking statements are based on the
estimates and opinions of management on the dates they are made and
are expressly qualified in their entirety by this notice. EMMAC
Life Sciences Group assumes no obligation to update forward-looking
statements should circumstances or management's estimates or
opinions change.
ENDS
For further information on the Company please visit www.fstfwd.co or contact:
Ed McDermott / Lance FastForward Innovations Email: info@fstfwd.co
de Jersey Ltd
James Biddle / Roland Beaumont Cornish Limited, Tel: +44 (0) 207 628
Cornish Nomad 3396
-------------------------- ----------------------
Isabella Pierre / Damon Shard Capital Partners Tel: (0)207 186 9927
Heath LLP
-------------------------- ----------------------
Isabel de Salis / Beth St Brides Partners Tel: +44 (0)207 236
Melluish Ltd, 1177
Financial PR
-------------------------- ----------------------
Notes
FastForward Innovations is an AIM quoted investment company
focused primarily on disruptive high growth life sciences and
technology businesses particularly within the medical cannabis
arena. The Company's strategy is to identify early stage
opportunities that have an upcoming investment catalyst and grow
its portfolio in terms of value whilst limiting the number of
investee companies to a level where relevant time can be devoted to
each.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRASEFFMMEFSEFF
(END) Dow Jones Newswires
January 26, 2021 11:12 ET (16:12 GMT)
Kuala Innov (LSE:KUL)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Kuala Innov (LSE:KUL)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
